PT - JOURNAL ARTICLE AU - Zhang, Yong AU - Lu, Zuneng AU - Wang, Bo AU - Cang, Jinxing AU - Ma, Yonggang TI - Gastrointestinal tract symptoms in coronavirus disease 2019: Analysis of clinical symptoms in adult patients AID - 10.1101/2020.03.23.20040279 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.23.20040279 4099 - http://medrxiv.org/content/early/2020/03/27/2020.03.23.20040279.short 4100 - http://medrxiv.org/content/early/2020/03/27/2020.03.23.20040279.full AB - Objective To investigate the clinical presentation of coronavirus disease 2019 (COVID-19), particularly the incidence of gastrointestinal tract symptoms.Design We enrolled adult COVID-19 patients from a mobile cabin hospital in Wuhan with a definitive diagnosis by SARS-CoV-2 nucleic acid testing. Face-to-face interviews were conducted in which the patient selected COVID-19-related symptoms and report the time of onset and duration of symptoms.Results A total of 212 adults were enrolled in this study, of which 127 (59.9%) were females, mean age was 48.50 ±13.15 (range: 17-79) years, and mean disease course was 26.78±9.16 (3-60) days. Fever and cough were the most common and earliest clinical symptoms of COVID-19.Diarrhoea occurred in 43.8% (93/212) of patients, of which 86.0% (80/93) had mushy stools. Nausea and vomiting were also common (20.7%). Diarrhoea lasted for 4.00(2.00-8.85) days and mostly occurred 5.00(0.25-11.00) days after the emergence of the first symptoms. Multiple logistic regression analysis found that diarrhoea was significantly correlated with fatigue [OR2.900,95%CI (1.629-5.164), p<0.0001].Conclusions Gastrointestinal tract symptoms are common in COVID-19 and most occur during the middle stage of the disease and lasts for a short period of time. Clinicians need to pay greater attention to gastrointestinal tract symptoms of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIt is not a clinical trials.Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to the study are included in the article or uploaded as supplementary information